Vanguard Group
ACHV icon

Vanguard Group’s Achieve Life Sciences ACHV Stock Holding History

Vanguard Group’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$12.3M Buy
2,474,312
+12,510
+0.5% +$54.5K ﹤0.01% 2859
2025
Q3 		$7.75M Buy
2,461,802
+311,925
+15% +$856K ﹤0.01% 3113
2025
Q2 		$4.86M Buy
2,149,877
+432,863
+25% +$1.23M ﹤0.01% 3227
2025
Q1 		$4.58M Sell
1,717,014
-32,777
-2% -$102K ﹤0.01% 3209
2024
Q4 		$6.16M Sell
1,749,791
-190,597
-10% -$864K ﹤0.01% 3179
2024
Q3 		$9.2M Buy
1,940,388
+434,657
+29% +$1.99M ﹤0.01% 3000
2024
Q2 		$7.08M Buy
1,505,731
+557,290
+59% +$2.68M ﹤0.01% 3094
2024
Q1 		$4.31M Buy
948,441
+342,731
+57% +$1.52M ﹤0.01% 3352
2023
Q4 		$2.5M Buy
605,710
+11,757
+2% +$51.2K ﹤0.01% 3525
2023
Q3 		$2.55M Buy
593,953
+16,160
+3% +$81.5K ﹤0.01% 3506
2023
Q2 		$3M Buy
577,793
+158,409
+38% +$1.11M ﹤0.01% 3521
2023
Q1 		$2.85M Buy
419,384
+79,146
+23% +$376K ﹤0.01% 3550
2022
Q4 		$834K Sell
340,238
-8,075
-2% -$20.7K ﹤0.01% 3968
2022
Q3 		$1.15M Sell
348,313
-2,307
-0.7% -$11K ﹤0.01% 3959
2022
Q2 		$1.71M Buy
350,620
+7,715
+2% +$52.3K ﹤0.01% 3873
2022
Q1 		$2.6M Sell
342,905
-2,870
-0.8% -$21.4K ﹤0.01% 3853
2021
Q4 		$2.69M Buy
345,775
+76,918
+29% +$604K ﹤0.01% 3927
2021
Q3 		$2.29M Buy
268,857
+19,975
+8% +$157K ﹤0.01% 4019
2021
Q2 		$2.24M Sell
248,882
-47,067
-16% -$448K ﹤0.01% 3940
2021
Q1 		$3.43M Buy
295,949
+268,741
+988% +$3.19M ﹤0.01% 3705
2020
Q4 		$220K Buy
27,208
+9,402
+53% +$79.6K ﹤0.01% 4076
2020
Q3 		$149K Sell
17,806
-1
-0% -$9 ﹤0.01% 3981
2020
Q2 		$141K Hold
17,807
– – ﹤0.01% 3958
2020
Q1 		$116K Buy
17,807
+16,351
+1,123% +$158K ﹤0.01% 3923
2019
Q4 		$15K Sell
1,456
-8,176
-85% -$175K ﹤0.01% 4101
2019
Q3 		$328K Sell
9,632
-4,094
-30% -$161K ﹤0.01% 3882
2019
Q2 		$530K Buy
13,726
+8,283
+152% +$586K ﹤0.01% 3814
2019
Q1 		$352K Buy
5,443
+3,665
+206% +$148K ﹤0.01% 3830
2018
Q4 		$43K Buy
1,778
+5
+0.3% +$189 ﹤0.01% 4082
2018
Q3 		$112K Buy
1,773
+1,115
+169% +$70.5K ﹤0.01% 4060
2018
Q2 		$50K Sell
658
-50
-7% -$10.2K ﹤0.01% 4098
2018
Q1 		$180K Buy
708
+31
+5% +$8.87K ﹤0.01% 3966
2017
Q4 		$183K Buy
677
+182
+37% +$58.2K ﹤0.01% 3946
2017
Q3 		$201K Buy
495
+227
+85% +$163K ﹤0.01% 3921
2017
Q2 		$212K Sell
268
-38
-12% -$30.8K ﹤0.01% 3891
2017
Q1 		$297K Buy
306
+1
+0.3% +$1.21K ﹤0.01% 3839
2016
Q4 		$336K Sell
305
-45
-13% -$44.5K ﹤0.01% 3806
2016
Q3 		$391K Sell
350
-32
-8% -$51K ﹤0.01% 3804
2016
Q2 		$841K Hold
382
– – ﹤0.01% 3651
2016
Q1 		$575K Buy
382
+36
+10% +$58.6K ﹤0.01% 3750
2015
Q4 		$920K Buy
346
+1
+0.3% +$4.23K ﹤0.01% 3653
2015
Q3 		$1.69M Buy
345
+121
+54% +$729K ﹤0.01% 3450
2015
Q2 		$1.15M Buy
224
+12
+6% +$59.5K ﹤0.01% 3623
2015
Q1 		$1M Buy
212
+21
+11% +$103K ﹤0.01% 3632
2014
Q4 		$960K Buy
191
+7
+4% +$34.2K ﹤0.01% 3539
2014
Q3 		$1.08M Buy
184
+29
+19% +$201K ﹤0.01% 3482
2014
Q2 		$1.27M Buy
155
+7
+5% +$86K ﹤0.01% 3422
2014
Q1 		$3.83M Buy
148
+51
+53% +$1.25M ﹤0.01% 2958
2013
Q4 		$1.78M Sell
97
-28
-22% -$491K ﹤0.01% 3234
2013
Q3 		$2.55M Hold
125
– – ﹤0.01% 3041
2013
Q2 		$2.7M Buy
+125
New +$2.8M ﹤0.01% 2961

Other funds holding ACHV

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Vanguard Group's ACHV Position: Q4 2025 in Review

Vanguard Group increased its Achieve Life Sciences (ACHV) stake by 0.51% in Q4 2025, buying an estimated $54.5K and bringing the position to 2,474,312 shares worth $12.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2859.

Vanguard Group first reported a position in ACHV in Q2 2013 and has held it in 51 quarters since. 77 funds tracked by Wall St. Rank hold ACHV as of Q4 2025.

  • Vanguard Group held 2,474,312 shares of Achieve Life Sciences worth $12.3M as of Q4 2025.
  • Vanguard Group bought 12,510 Achieve Life Sciences shares in Q4 2025, an estimated $54.5K.
  • Achieve Life Sciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2859 holding.
  • Vanguard Group first reported a position in Achieve Life Sciences in Q2 2013 and has held it in 51 quarters since.
  • 77 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.